Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments ...
According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...
Latigo Biotherapeutics, Vivace Therapeutics, and Vori Health each announced the recent successful closing of their respective ...
SMi Group Reports: The leading Pain Therapeutics Conference will take place for its 22nd consecutive year on 4th and 5th May 2022 in London, UK to explore novel compounds and treatments for pain ...
Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for ...
Shares of Chromocell Therapeutics Co. (NYSE:CHRO – Get Free Report) fell 8.2% during trading on Friday . The stock traded as low as $1.57 and last traded at $1.57. 5,935 shares changed hands during ...
Dogwood Therapeutics, Inc. has announced the dosing ... which studies Halneuron® as a treatment for chemotherapy-induced neuropathic pain. Halneuron® is designed to target the NaV 1.7 sodium ...
THOUSAND OAKS, Calif., March 17, 2025 /PRNewswire/ -- Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments that target pain ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback